The primary focus of CTL's Therapeutics program is development of fully-human monoclonal antibodies (mAbs) for different therapeutic indications. Monoclonal Antibodies represent an attractive class of therapeutics due to their high target specificity. However, most of the currently used mAbs have been developed as murine (mouse origin), chimeric (34% mouse origin) or humanized (5-10% mouse origin) constructs, and carry an inherent risk of generating an immunogenic response, with associated adverse events and reduced therapeutic potential due to tumor resistance.
Our current focus is on development of mAbs for use in B-Cell Malignancies as monospecific, multispecific as well as chemo-mAb linked constructs. We anticipate that these fully human products will significantly reduce the problems of adverse effects and tumor resistance associated with currently available products.